ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Byetta 5 micrograms solution for injection in pre-filled pen

Byetta 10 micrograms solution for injection in pre-filled pen

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose contains 5 micrograms (mcg) of exenatide in 20 microlitres (mcl), (0.25 mg exenatide per mL).

Each dose contains 10 micrograms (mcg) of exenatide in 40 microlitres (mcl), (0.25 mg exenatide per mL).

Excipient with known effect:
Byetta 5 mcg: Each dose contains 44 mcg metacresol.
Byetta 10 mcg: Each dose contains 88 mcg metacresol.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection (injection).

Clear, colourless solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Byetta is indicated for treatment of type 2 diabetes mellitus in combination with:
- metformin
- sulphonylureas
- thiazolidinediones
- metformin and a sulphonylurea
- metformin and a thiazolidinedione
in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults who have not achieved adequate glycaemic control with these medicinal products.

4.2 Posology and method of administration

Posology
Immediate-release exenatide (Byetta) therapy should be initiated at 5 mcg exenatide per dose administered twice daily (BID) for at least one month in order to improve tolerability. The dose of exenatide can then be increased to 10 mcg BID to further improve glycaemic control. Doses higher than 10 mcg BID are not recommended.

Immediate-release exenatide is available as either a 5 mcg or a 10 mcg exenatide per dose pre-filled pen.
Immediate-release exenatide can be administered at any time within the 60-minute period before the morning and evening meal (or two main meals of the day, approximately 6 hours or more apart). Immediate-release exenatide should not be administered after a meal. If an injection is missed, the treatment should be continued with the next scheduled dose.

Immediate-release exenatide is recommended for use in patients with type 2 diabetes mellitus who are already receiving metformin, a sulphonylurea, pioglitazone and/or a basal insulin. Immediate-release exenatide use can be continued when a basal insulin is added to existing therapy. When immediate-release exenatide is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued as no increased risk of hypoglycaemia is anticipated, compared to metformin or pioglitazone alone. When immediate-release exenatide is added to sulphonylurea therapy, a reduction in the dose of sulphonylurea should be considered to reduce the risk of hypoglycaemia (see section 4.4.). When immediate-release exenatide is used in combination with basal insulin, the dose of basal insulin should be evaluated. In patients at increased risk of hypoglycaemia reducing the dose of basal insulin should be considered (see section 4.8).

The dose of immediate-release exenatide does not need to be adjusted on a day-by-day basis depending on self-monitored glycaemia. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea or insulin, particularly when Byetta therapy is started and insulin is reduced. A stepwise approach to insulin dose reduction is recommended.

**Special populations**

**Elderly**
Immediate-release exenatide should be used with caution and dose escalation from 5 mcg to 10 mcg should proceed conservatively in patients > 70 years. The clinical experience in patients > 75 years is very limited.

**Renal impairment**
No dosage adjustment is necessary in patients with mild renal impairment (creatinine clearance 50-80 mL/min).

In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), dose escalation from 5 mcg to 10 mcg should proceed conservatively (see section 5.2).

Exenatide is not recommended for use in patients with end-stage renal disease or severe renal impairment (creatinine clearance < 30 mL/min) (see section 4.4).

**Hepatic impairment**
No dosage adjustment is necessary in patients with hepatic impairment (see section 5.2).

**Paediatric population**
The efficacy of exenatide in children and adolescents under 18 years of age was not demonstrated. Currently available data are described in sections 5.1 and 5.2 but no recommendation on a posology can be made.

**Method of administration**
Each dose should be administered as a subcutaneous injection in the thigh, abdomen, or upper arm. Immediate-release exenatide and basal insulin must be administered as two separate injections.

For instructions for using the pen, see section 6.6 and the user manual included with the leaflet.

4.3 **Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use

Exenatide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Exenatide is not a substitute for insulin. Diabetic ketoacidosis has been reported in insulin-dependent patients after rapid discontinuation or dose reduction of insulin (see section 4.2).

Immediate-release exenatide must not be administered by intravenous or intramuscular injection.

Renal impairment
In patients with end-stage renal disease receiving dialysis, single doses of immediate-release exenatide 5 mcg increased frequency and severity of gastrointestinal adverse reactions. Exenatide is not recommended for use in patients with end-stage renal disease or severe renal impairment (creatinine clearance < 30 mL/min). The clinical experience in patients with moderate renal impairment is very limited (see section 4.2).

There have been uncommon, spontaneously reported events of altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure and acute renal failure, sometimes requiring hemodialysis. Some of these events occurred in patients experiencing events that may affect hydration, including nausea, vomiting, and/or diarrhoea and/or receiving medicinal products known to affect renal function/hydration status. Concomitant medicinal products included angiotensin converting enzymes inhibitors, angiotensin-II antagonists, nonsteroidal anti-inflammatory medicinal products and diuretics. Reversibility of altered renal function has been observed with supportive treatment and discontinuation of potentially causative medicinal products, including exenatide.

Acute pancreatitis
Use of GLP-1 receptor agonists has been associated with a risk of developing acute pancreatitis. There have been spontaneously reported events of acute pancreatitis with exenatide. Resolution of pancreatitis has been observed with supportive treatment but very rare cases of necrotising or hemorrhagic pancreatitis and/or death have been reported. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. If pancreatitis is suspected, exenatide should be discontinued; if acute pancreatitis is confirmed, exenatide should not be restarted. Caution should be exercised in patients with a history of pancreatitis.

Severe gastrointestinal disease
Exenatide has not been studied in patients with severe gastrointestinal disease, including gastroparesis. Its use is commonly associated with gastrointestinal adverse reactions, including nausea, vomiting, and diarrhoea. Therefore, the use of exenatide is not recommended in patients with severe gastrointestinal disease.

Hypoglycaemia
When immediate-release exenatide was used in combination with a sulphonylurea, the incidence of hypoglycaemia was increased over that of placebo in combination with a sulphonylurea. In the clinical studies patients on a sulphonylurea combination, with mild renal impairment had an increased incidence of hypoglycaemia compared to patients with normal renal function. To reduce the risk of hypoglycaemia associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea should be considered.

Rapid weight loss
Weight loss greater than 1.5 kg per week has been observed in approximately 5% of clinical trial patients treated with exenatide. Weight loss of this rate may have harmful consequences. Patients with rapid weight loss should be monitored for signs and symptoms of cholelithiasis.

Concomitant medicinal products
The effect of immediate-release exenatide to slow gastric emptying may reduce the extent and rate of absorption of orally administered medicinal products. Immediate-release exenatide should be used
with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption and medicinal products with a narrow therapeutic ratio. Specific recommendations regarding intake of such medicinal products in relation to immediate-release exenatide is given in section 4.5.

The concurrent use of immediate-release exenatide with D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied and cannot be recommended.

**Excipients**
This medicinal product contains metacresol, which may cause allergic reactions.

This medicinal product contains less than 1 mmol sodium per dose, i.e. essentially “sodium-free”.

### 4.5 Interaction with other medicinal products and other forms of interaction

The effect of immediate-release exenatide to slow gastric emptying may reduce the extent and rate of absorption of orally administered medicinal products. Patients receiving medicinal products of either a narrow therapeutic ratio or medicinal products that require careful clinical monitoring should be followed closely. These medicinal products should be taken in a standardised way in relation to immediate-release exenatide injection. If such medicinal products are to be administered with food, patients should be advised to, if possible, take them with a meal when immediate-release exenatide is not administered.

For oral medicinal products that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, patients should be advised to take those medicinal products at least 1 hour before immediate-release exenatide injection.

Gastroresistant formulations containing substances sensitive for degradation in the stomach, such as proton pump inhibitors, should be taken at least 1 hour before or more than 4 hours after immediate-release exenatide injection.

**Digoxin, lisinopril and warfarin**
A delay in $t_{\text{max}}$ of about 2 h was observed when digoxin, lisinopril or warfarin was administered 30 min after exenatide. No clinically relevant effects on $C_{\text{max}}$ or AUC were observed. However, since market introduction, increased INR (International Normalized Ratio) has been reported spontaneously during concomitant use of warfarin and exenatide. INR should be closely monitored during initiation and dose increase of immediate-release exenatide therapy in patients on warfarin and/or cumarol derivatives (see section 4.8).

**Metformin or sulphonylureas**
Immediate-release exenatide is not expected to have any clinically relevant effects on the pharmacokinetics of metformin or sulphonylureas. Hence, no restriction in timing of intake of these medicinal products in relation to immediate-release exenatide injection are needed.

**Paracetamol**
Paracetamol was used as a model medicinal product to evaluate the effect of exenatide on gastric emptying. When 1000 mg paracetamol was given with 10 mcg immediate-release exenatide (0 h) and 1 h, 2 h and 4 h after immediate-release exenatide injection, paracetamol AUCs were decreased by 21%, 23%, 24% and 14% respectively; $C_{\text{max}}$ was decreased by 37%, 56%, 54% and 41%, respectively; $t_{\text{max}}$ was increased from 0.6 h in the control period to 0.9 h, 4.2 h, 3.3 h, and 1.6 h, respectively. Paracetamol AUC, $C_{\text{max}}$ and $t_{\text{max}}$ were not significantly changed when paracetamol was given 1 hour before immediate-release exenatide injection. No adjustment to paracetamol dosing is required based on these study results.

**Hydroxy Methyl Glutaryl Coenzyme A (HMG CoA) reductase inhibitors**
Lovastatin AUC and $C_{\text{max}}$ were decreased approximately 40% and 28%, respectively, and $t_{\text{max}}$ was delayed about 4 h when immediate-release exenatide (10 mcg BID) was administered concomitantly
with a single dose of lovastatin (40 mg) compared with lovastatin administered alone. In the 30-week placebo-controlled clinical trials, concomitant use of immediate-release exenatide and HMG CoA reductase inhibitors was not associated with consistent changes in lipid profiles (see section 5.1). Changes in LDL-C or total cholesterol are possible, however, no predetermined dose adjustment is required. Lipid profiles should be monitored regularly.

**Ethinyl estradiol and levonorgestrel**
Administration of a combination oral contraceptive (30 mcg ethinyl estradiol plus 150 mcg levonorgestrel) one hour before immediate-release exenatide (10 mcg BID) did not alter the AUC, \(C_{\text{max}}\) or \(C_{\text{min}}\) of either ethinyl estradiol or levonorgestrel. Administration of the oral contraceptive 30 minutes after immediate-release exenatide did not affect AUC but resulted in a reduction of the \(C_{\text{max}}\) of ethinyl estradiol by 45%, and \(C_{\text{max}}\) of levonorgestrel by 27-41%, and a delay in \(t_{\text{max}}\) by 2-4 h due to delayed gastric emptying. The reduction in \(C_{\text{max}}\) is of limited clinical relevance and no adjustment of dosing of oral contraceptives is required.

**Paediatric population**
Interaction studies have only been performed in adults.

### 4.6 Fertility, pregnancy and lactation

**Women of childbearing potential**
If a patient wishes to become pregnant, or pregnancy occurs, treatment with exenatide should be discontinued.

**Pregnancy**
There are no adequate data from the use of exenatide in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Exenatide should not be used during pregnancy and the use of insulin is recommended.

**Breast-feeding**
It is unknown whether exenatide is excreted in human milk. Exenatide should not be used if breast-feeding.

**Fertility**
No fertility studies in humans have been conducted.

### 4.7 Effects on ability to drive and use machines

Exenatide has minor influence on the ability to drive and use machines. When exenatide is used in combination with a sulphonylurea or a basal insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines.

### 4.8 Undesirable effects

**Summary of the safety profile**
The most frequent adverse reactions were mainly gastrointestinal related (nausea, vomiting and diarrhoea). The most frequently reported single adverse reaction was nausea which was associated with the initiation of treatment and decreased over time. Patients may experience hypoglycaemia when immediate-release exenatide is used with a sulphonylurea. Most adverse reactions associated with immediate-release exenatide were mild to moderate in intensity.

Since immediate-release exenatide has been marketed, acute pancreatitis has been reported with a frequency not known and acute renal failure has been reported uncommonly (see section 4.4).

**Tabulated list of adverse reactions**
Table 1 lists adverse reactions reported of immediate-release exenatide from clinical trials and spontaneous reports (not observed in clinical trials, frequency not known).
In clinical trials, background therapies included metformin, a sulphonylurea, a thiazolidinedione, or a combination of oral glucose-lowering medicinal products.

The reactions are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

Table 1: Adverse reactions of immediate-release exenatide identified from clinical trials and spontaneous reports

<table>
<thead>
<tr>
<th>System organ class /adverse reaction terms</th>
<th>Frequency of occurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Very common</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
</tr>
<tr>
<td>Drug-induced thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td></td>
</tr>
<tr>
<td>Cholecystitis</td>
<td></td>
</tr>
<tr>
<td>Cholelithiasis</td>
<td></td>
</tr>
<tr>
<td>Immune system disorders</td>
<td></td>
</tr>
<tr>
<td>Anaphylactic reaction</td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
</tr>
<tr>
<td>Hypoglycaemia (with metformin and a sulphonylurea)²</td>
<td></td>
</tr>
<tr>
<td>Hypoglycaemia (with a sulphonylurea)</td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td></td>
</tr>
<tr>
<td>Dehydration, generally associated with nausea, vomiting and/or diarrhoea.</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td></td>
</tr>
<tr>
<td>System organ class / adverse reaction terms</td>
<td>Frequency of occurrence</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td>Very common</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Intestinal obstruction</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
</tr>
<tr>
<td>Gastroesophageal reflux disease</td>
<td></td>
</tr>
<tr>
<td>Abdominal distension</td>
<td></td>
</tr>
<tr>
<td>Acute pancreatitis (see section 4.4)</td>
<td></td>
</tr>
<tr>
<td>Ercutation</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td></td>
</tr>
<tr>
<td>Flatulence</td>
<td></td>
</tr>
<tr>
<td>Delayed gastric emptying</td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Hyperhidrosis²</td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td></td>
</tr>
<tr>
<td>Macular and papular rash</td>
<td>X³</td>
</tr>
<tr>
<td>Pruritus, and/ or urticaria</td>
<td></td>
</tr>
<tr>
<td>Angioneurotic oedema</td>
<td>X³</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Altered renal function, including acute renal failure, worsened chronic renal failure, renal impairment, increased serum creatinine</td>
<td>X¹</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
</tr>
<tr>
<td>Feeling jittery</td>
<td></td>
</tr>
<tr>
<td>Asthenia²</td>
<td></td>
</tr>
<tr>
<td>Injection site reactions</td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
</tr>
<tr>
<td>Weight decreased</td>
<td></td>
</tr>
<tr>
<td>International normalised ratio increased with concomitant warfarin, some reports associated with bleeding</td>
<td></td>
</tr>
</tbody>
</table>

¹ Rate based on immediate-release exenatide completed long-term efficacy and safety studies n=5763 total (patients on sulphonylurea n=2971).
² In insulin-comparator controlled studies in which metformin and a sulphonylurea were concomitant medicinal products, the incidence for these adverse reactions was similar for insulin- and immediate-release exenatide-treated patients.
³ Spontaneous reports data (unknown denominator)
When immediate-release exenatide was used in combination with basal insulin therapy the incidence and types of other adverse events observed were similar to those seen in the controlled clinical trials with exenatide as monotherapy, with metformin and/or sulphonylurea or a thiazolidinedione, with or without metformin.

**Description of selected adverse reactions**

**Drug-induced thrombocytopenia**

Drug-induced thrombocytopenia (DITP) with exenatide-dependent anti-platelet antibodies has been reported in the postmarketing setting. DITP is an immune-mediated reaction that is caused by drug-dependent platelet-reactive antibodies. These antibodies cause destruction of platelets in the presence of the sensitizing drug.

**Hypoglycaemia**

In studies in patients treated with immediate-release exenatide and a sulphonylurea (with or without metformin), the incidence of hypoglycaemia was increased compared to placebo (23.5% and 25.2% versus 12.6% and 3.3%) and appeared to be dependent on the doses of both immediate-release exenatide and the sulphonylurea.

There were no clinically relevant differences in incidence or severity of hypoglycaemia with exenatide compared to placebo, in combination with a thiazolidinedione, with or without metformin. Hypoglycaemia was reported in 11% and 7% of patients treated with exenatide and placebo respectively.

Most episodes of hypoglycaemia were mild to moderate in intensity, and resolved with oral administration of carbohydrate.

In a 30-week study, when immediate-release exenatide or placebo was added to existing basal insulin therapy (insulin glargine), the dose of basal insulin was decreased by 20% in patients with an HbA1c ≤ 8.0%, per protocol design in order to minimize the risk of hypoglycaemia. Both treatment arms were titrated to achieve target fasting plasma glucose levels (see section 5.1). There were no clinically significant differences in the incidence of hypoglycaemic episodes in the immediate-release exenatide compared to the placebo group (25% and 29% respectively). There were no episodes of major hypoglycaemic episodes in the immediate-release exenatide arm.

In a 24-week study, where either insulin lispro protamine suspension or insulin glargine was added to existing therapy of immediate-release exenatide and metformin or metformin plus thiazolidinedione the incidence of patients with at least one minor hypoglycaemic episode was 18% and 9% respectively and one patient reported major hypoglycaemia. In patients where existing therapy also included a sulphonylurea the incidence of patients with at least one minor hypoglycaemic episode was 48% and 54% respectively and one patient reported major hypoglycaemia.

**Nausea**

The most frequently reported adverse reaction was nausea. In patients treated with 5 mcg or 10 mcg immediate-release exenatide, 36% reported at least one episode of nausea. Most episodes of nausea were mild to moderate and occurred in a dose-dependent fashion. With continued therapy, the frequency and severity decreased in most patients who initially experienced nausea.

The incidence of withdrawal due to adverse events was 8% for immediate-release exenatide-treated patients, 3% for placebo-treated and 1% for insulin-treated patients in the long-term controlled trials (16 weeks or longer). The most common adverse events leading to withdrawal for immediate-release exenatide-treated patients were nausea (4% of patients) and vomiting (1%). For placebo-treated or insulin-treated patients, < 1% withdrew due to nausea or vomiting.

Immediate-release exenatide-treated patients in the open-label extension studies at 82 weeks experienced similar types of adverse events observed in the controlled trials.
**Injection site reactions**
Injection site reactions have been reported in approximately 5.1% of subjects receiving immediate-release exenatide in long-term (16 weeks or longer) controlled trials. These reactions have usually been mild and usually did not result in discontinuation of immediate-release exenatide.

**Immunogenicity**
Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-exenatide antibodies following treatment with immediate-release exenatide. In most patients who develop antibodies, antibody titres diminish over time and remain low through 82 weeks.

Overall, the percentage of antibody positive patients was consistent across clinical trials. Patients who develop antibodies to exenatide tend to have more injection site reactions (for example: redness of skin and itching), but otherwise similar rates and types of adverse events as those with no anti-exenatide antibodies. In the three placebo-controlled trials ($n=963$) 38% of patients had low titre anti-exenatide antibodies at 30 weeks. For this group, the level of glycaemic control ($\text{HbA}_1\text{c}$) was generally comparable to that observed in those without antibody titres. An additional 6% of patients had higher titre antibodies at 30 weeks. About half of this 6% (3% of the total patients given immediate-release exenatide in the controlled studies), had no apparent glycaemic response to immediate-release exenatide. In three insulin-comparator controlled trials ($n=790$) comparable efficacy and adverse events were observed in immediate-release exenatide-treated patients regardless of antibody titre.

Examination of antibody-positive specimens from one long-term uncontrolled study revealed no significant cross-reactivity with similar endogenous peptides (glucagon or GLP-1).

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 **Overdose**
Signs and symptoms of overdose may include severe nausea, severe vomiting and rapidly declining blood glucose concentrations. In the event of overdose, appropriate supportive treatment (possibly given parenterally) should be initiated according to the patient’s clinical signs and symptoms.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**
Pharmacotherapeutic group: Glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ01.

**Mechanism of action**
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind to and activate the known human GLP-1 receptor *in vitro*, its mechanism of action mediated by cyclic AMP and/or other intracellular signalling pathways.

Exenatide increases, on a glucose-dependent basis, the secretion of insulin from pancreatic beta cells. As blood glucose concentrations decrease, insulin secretion subsides. When exenatide was used in combination with metformin alone, no increase in the incidence of hypoglycaemia was observed over that of placebo in combination with metformin which may be due to this glucose-dependent insulinotropic mechanism (see section 4.4).
Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in type 2 diabetes. Lower glucagon concentrations lead to decreased hepatic glucose output. However, exenatide does not impair the normal glucagon response and other hormone responses to hypoglycaemia.

Exenatide slows gastric emptying thereby reducing the rate at which meal-derived glucose appears in the circulation.

**Pharmacodynamic effects**
Immediate-release exenatide improves glycaemic control through the immediate and sustained effects of lowering both postprandial and fasting glucose concentrations in patients with type 2 diabetes.

**Clinical efficacy and safety**

**Studies of immediate-release exenatide with metformin, a sulphonylurea or both as background therapy**
The clinical studies comprised 3945 subjects (2997 treated with exenatide), 56% men and 44% women, 319 subjects (230 treated with exenatide) were ≥ 70 years of age and 34 subjects (27 treated with exenatide) were ≥ 75 years of age.

Immediate-release exenatide reduced HbA\(_1c\) and body weight in patients treated for 30 weeks in three placebo-controlled studies, whether the immediate-release exenatide was added to metformin, a sulphonylurea or a combination of both. These reductions in HbA\(_1c\) were generally observed at 12 weeks after initiation of treatment. See Table 2. The reduction in HbA\(_1c\) was sustained and the weight loss continued for at least 82 weeks in the subset of 10 mcg BID patients completing both the placebo-controlled studies and the uncontrolled study extensions (n=137).

**Table 2: Combined results of the 30-week placebo-controlled studies (intent to treat patients)**

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Immediate-release exenatide 5 mcg BID</th>
<th>Immediate-release exenatide 10 mcg BID</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>483</td>
<td>480</td>
<td>483</td>
</tr>
<tr>
<td>Baseline HbA(_1c) (%)</td>
<td>8.48</td>
<td>8.42</td>
<td>8.45</td>
</tr>
<tr>
<td>HbA(_1c) (%) change from base line</td>
<td>0.08</td>
<td>-0.59</td>
<td>-0.89</td>
</tr>
<tr>
<td>Proportion of patients (%) achieving HbA(_1c) ≤ 7%</td>
<td>7.9</td>
<td>25.3</td>
<td>33.6</td>
</tr>
<tr>
<td>Proportion of patients (%) achieving HbA(_1c) ≤ 7% (patients completing studies)</td>
<td>10.0</td>
<td>29.6</td>
<td>38.5</td>
</tr>
<tr>
<td>Baseline weight (kg)</td>
<td>99.26</td>
<td>97.10</td>
<td>98.11</td>
</tr>
<tr>
<td>Change of weight from baseline (kg)</td>
<td>-0.65</td>
<td>-1.41</td>
<td>-1.91</td>
</tr>
</tbody>
</table>

In insulin-comparator studies immediate-release exenatide (5 mcg BID for 4 weeks, followed by 10 mcg BID) in combination with metformin and sulphonylurea significantly (statistically and clinically) improved glycaemic control, as measured by decrease in HbA\(_1c\). This treatment effect was comparable to that of insulin glargine in a 26-week study (mean insulin dose 24.9 IU/day, range 4-95 IU/day, at the end of study) and biphasic insulin aspart in a 52-week study (mean insulin dose 24.4 IU/day, range 3-78 IU/day, at the end of study). Immediate-release exenatide lowered HbA\(_1c\) from 8.21 (n=228) and 8.6% (n=222) by 1.13 and 1.01% while insulin glargine lowered from 8.24 (n=227) by 1.10% and biphasic insulin aspart from 8.67 (n=224) by 0.86%. Weight loss of 2.3 kg (2.6%) was achieved with immediate-release exenatide in the 26-week study and a loss of 2.5 kg (2.7%) in a
52-week study whereas treatment with insulin was associated with weight gain. Treatment differences (immediate-release exenatide minus comparator) were -4.1 kg in the 26-week study and -5.4 kg in the 52-week study. Seven-point self-monitored blood glucose profiles (before and after meals and at 3 am) demonstrated significantly reduced glucose values compared to insulin in the postprandial periods after immediate-release exenatide injection. Premeal blood glucose concentrations were generally lower in patients taking insulin compared to immediate-release exenatide. Mean daily blood glucose values were similar between immediate-release exenatide and insulin. In these studies the incidence of hypoglycaemia was similar for immediate-release exenatide and insulin treatment.

Studies of immediate-release exenatide with metformin, a thiazolidinedione or both as background therapy
Two placebo-controlled studies were conducted: one of 16 and one of 26 weeks duration, with 121 and 111 immediate-release exenatide and 112 and 54 placebo treated patients respectively, added to existing thiazolidinedione treatment, with or without metformin. Of the immediate-release exenatide patients, 12% were treated with a thiazolidinedione and immediate-release exenatide and 82% were treated with a thiazolidinedione, metformin and immediate-release exenatide. Immediate-release exenatide (5 mcg BID for 4 weeks, followed by 10 mcg BID) resulted in statistically significant reductions from baseline HbA\textsubscript{1c} compared to placebo (-0.7% versus +0.1%) as well as significant reductions in body weight (-1.5 versus 0 kg) in the 16 week study. The 26-week study showed similar results with statistically significant reductions from baseline HbA\textsubscript{1c} compared to placebo (-0.8% versus -0.1%). There was no significant difference in body weight between treatment groups in change from baseline to endpoint (-1.4 versus -0.8 kg).

When immediate-release exenatide was used in combination with a thiazolidinedione, the incidence of hypoglycaemia was similar to that of placebo in combination with a thiazolidinedione. The experience in patients > 65 years and in patients with impaired renal function is limited. The incidence and type of other adverse events observed were similar to those seen in the 30-week controlled clinical trials with a sulphonylurea, metformin or both.

Studies of immediate-release exenatide in combination with basal insulin
In a 30-week study, either immediate-release exenatide (5 mcg BID for 4 weeks, followed by 10 mcg BID) or a placebo was added to insulin glargine (with or without metformin, pioglitazone or both). During the study both treatment arms titrated insulin glargine using an algorithm reflecting current clinical practice to a target fasting plasma glucose of approximately 5.6 mmol/L. The mean age of subjects was 59 years and the mean duration of diabetes was 12.3 years.

At the end of the study, immediate-release exenatide (n=137) demonstrated a statistically significant reduction in the HbA\textsubscript{1c} and weight compared to placebo (n=122). Immediate-release exenatide lowered HbA\textsubscript{1c} by 1.7% from a baseline of 8.3% while placebo lowered HbA\textsubscript{1c} by 1.0% from a baseline of 8.5%. The proportion of patients achieving HbA\textsubscript{1c} < 7% and HbA\textsubscript{1c} ≤ 6.5% was 56% and 42% with immediate-release exenatide and 29% and 13% with placebo. Weight loss of 1.8 kg from a baseline of 95 kg was observed with immediate-release exenatide whereas a weight gain of 1.0 kg from a baseline of 94 kg was observed with placebo.

In the immediate-release exenatide arm the insulin dose increased by 13 units/day compared to 20 units/day on the placebo arm. Immediate-release exenatide reduced fasting serum glucose by 1.3 mmol/L and placebo by 0.9 mmol/L. The immediate-release exenatide arm compared to placebo had significantly lowered postprandial blood glucose excursions at the morning meal (- 2.0 versus - 0.2 mmol/L) and evening meal (- 1.6 versus + 0.1 mmol/L), there was no difference between treatments at midday.

In a 24-week study, where either insulin lispro protamine suspension or insulin glargine was added to existing therapy of immediate-release exenatide and metformin, metformin and sulphonylurea or metformin and pioglitazone, HbA\textsubscript{1c} was lowered by 1.2% (n=170) and by 1.4% (n=167) respectively from a baseline of 8.2%. Weight increase of 0.2 kg was observed for patients on insulin lispro protamine suspension and 0.6 kg for insulin glargine treated patients from a baseline of 102 kg and 103 kg respectively.
In a 30-week, open-label, active comparator-controlled, noninferiority study, the safety and efficacy of immediate-release exenatide (n=315) versus titrated insulin lispro three times daily (n=312) on a background of optimized basal insulin glargine and metformin in patients with type 2 diabetes was evaluated.

Following a basal insulin optimization (BIO) phase, patients with HbA1c > 7.0% were randomized to add either immediate-release exenatide or insulin lispro to their existing regimen of insulin glargine and metformin. In both treatment groups, subjects continued to titrate their insulin glargine doses using an algorithm reflecting current clinical practice.

All patients assigned to immediate-release exenatide initially received 5 mcg BID for four weeks. After four weeks, their dose was increased to 10 mcg BID. Patients in the immediate-release exenatide-treated group with an HbA1c ≤ 8.0% at the end of the BIO phase decreased their insulin glargine dose by at least 10%.

Immediate-release exenatide lowered HbA1c by 1.1% from a baseline of 8.3% and insulin lispro lowered HbA1c by 1.1% from a baseline of 8.2% and noninferiority of immediate-release exenatide to titrated lispro was demonstrated. The proportion of patients achieving HbA1c < 7% was 47.9% with immediate-release exenatide and 42.8% with insulin lispro. Weight loss of 2.6 kg from a baseline of 89.9 kg was observed with immediate-release exenatide whereas a weight gain of 1.9 kg from a baseline of 89.3 kg was observed with insulin lispro.

**Fasting lipids**
Immediate-release exenatide has shown no adverse effects on lipid parameters. A trend for a decrease in triglycerides has been observed with weight loss.

**Beta-cell function**
Clinical studies with immediate-release exenatide have indicated improved beta-cell function, using measures such as the homeostasis model assessment for beta-cell function (HOMA-B) and the proinsulin to insulin ratio.

A pharmacodynamic study demonstrated in patients with type 2 diabetes (n=13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous bolus of glucose.

**Body weight**
A reduction in body weight was seen in patients treated with immediate-release exenatide irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction 2.4 kg versus 1.7 kg) in the long-term controlled studies of up to 52 weeks.

Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety.

**Paediatric population**
The efficacy and safety of immediate release exenatide was evaluated in a 28-week randomized, double-blind, placebo controlled study conducted in 120 patients aged 10 to 17 years with type 2 diabetes who had HbA1c 6.5% to 10.5% and who were either naive to anti-diabetes agents or were treated with metformin alone, a sulfonylurea alone, or metformin in combination with a sulfonylurea. Patients received twice daily treatment with immediate release exenatide 5 µg, immediate release exenatide 10 µg or equivalent dose of placebo for 28 weeks. The primary efficacy endpoint was the change in HbA1c from baseline to 28 weeks of treatment; the treatment difference (pooled doses) from placebo was not statistically significant [-0.28% (95% CI: -1.01, 0.45)]. No new safety findings were identified in this paediatric study.

### 5.2 Pharmacokinetic properties

**Absorption**
Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2 h. Mean peak exenatide concentration ($C_{max}$) was 211 pg/mL and
overall mean area under the curve (AUC\textsubscript{0-inf}) was 1036 pg h/mL following subcutaneous administration of a 10 mcg dose of exenatide. Exenatide exposure increased proportionally over the therapeutic dose range of 5 mcg to 10 mcg. Similar exposure is achieved with subcutaneous administration of exenatide in the abdomen, thigh, or arm.

**Distribution**
The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of exenatide is 28 L.

**Biotransformation and elimination**
Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. In clinical studies the mean apparent clearance of exenatide is 9 L/h and the mean terminal half-life is 2.4 h. These pharmacokinetic characteristics of exenatide are independent of the dose.

**Special populations**

**Renal impairment**
In patients with mild (creatinine clearance 50 to 80 mL/min) or moderate renal impairment (creatinine clearance 30 to 50 mL/min), exenatide clearance was mildly reduced compared to clearance in individuals with normal renal function (13% reduction in mild and 36% reduction in moderate renal impairment). Clearance was significantly reduced by 84% in patients with end-stage renal disease receiving dialysis (see section 4.2).

**Hepatic insufficiency**
No pharmacokinetic study has been performed in patients with hepatic insufficiency. Exenatide is cleared primarily by the kidney, therefore hepatic dysfunction is not expected to affect blood concentrations of exenatide.

**Gender and race**
Gender and race have no clinically relevant influence on exenatide pharmacokinetics.

**Elderly**
Long-term controlled data in elderly are limited, but suggest no marked changes in exenatide exposure with increased age up to about 75 years old. In a pharmacokinetic study in patients with type 2 diabetes, administration of exenatide (10 mcg) resulted in a mean increase of exenatide AUC by 36% in 15 elderly subjects aged 75 to 85 years compared to 15 subjects aged 45 to 65 years likely related to reduced renal function in the older age group (see section 4.2).

**Paediatric population**
In a single-dose pharmacokinetic study in 13 patients with type 2 diabetes and between the ages of 12 and 16 years, administration of exenatide (5 mcg) resulted in slightly lower mean AUC (16% lower) and C\textsubscript{max} (25% lower) compared to those observed in adults.

5.3 **Preclinical safety data**
Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity.

In female rats given exenatide for 2 years, an increased incidence of benign thyroid C-cell adenomas was observed at the highest dose, 250 mcg/kg/day, a dose that produced an exenatide plasma exposure 130-fold the human clinical exposure. This incidence was not statistically significant when adjusted for survival. There was no tumorigenic response in male rats or either sex of mice.

Animal studies did not indicate direct harmful effects with respect to fertility or pregnancy. High doses of exenatide during mid-gestation caused skeletal effects and reduced foetal growth in mice and reduced foetal growth in rabbits. Neonatal growth was reduced in mice exposed to high doses during late gestation and lactation.
6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

metacresol
mannitol
glacial acetic acid
sodium acetate trihydrate
water for injections

6.2 **Incompatibilities**

In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.

6.3 **Shelf life**

3 years

In use pen:
30 days

6.4 **Special precautions for storage**

Store in a refrigerator (2 ºC – 8 ºC).
Do not freeze.

In use pen:
Store below 25 ºC.

The pen must not be stored with the needle attached.
Replace cap on pen in order to protect from light.

6.5 **Nature and contents of container**

Type I glass cartridge with a (bromobutyl) rubber plunger, rubber disc, and aluminium seal. Each cartridge is assembled into a disposable pen-injector (pen).

5 mcg: Each pre-filled pen contains 60 doses (approximately 1.2 mL of solution).
10 mcg: Each pre-filled pen contains 60 doses (approximately 2.4 mL of solution).

Pack size of 1 and 3 pens. Not all pack sizes may be marketed.

Injection needles are not included.

Becton, Dickinson and Company needles are suitable to use with the Byetta pen.

6.6 **Special precautions for disposal and other handling.**

The patient should be instructed to discard the needle after each injection.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Instructions for use
Byetta is for use by one person only.

The instructions for using the pen, included with the leaflet, must be followed carefully.

The pen must not be stored with the needle attached.

Byetta should not be used if particles appear or if the solution is cloudy and/or coloured.

Do not use Byetta if it has been frozen.

7. MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/06/362/001 –4

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 20 November 2006
Date of latest renewal: 22 July 2016

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers responsible for batch release

AstraZeneca AB
Karlebyhusentrén Astraallén
SE-152 57 Södertälje
Sweden

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON

1. NAME OF THE MEDICINAL PRODUCT

Byetta 5 micrograms solution for injection in pre-filled pen exenatide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each dose contains 5 micrograms exenatide.

3. LIST OF EXCIPIENTS

Mannitol, glacial acetic acid, sodium acetate trihydrate, water for injections. Also contains metacresol. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
1 pen (60 doses)
3 pens (3 x 60 doses)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Twice daily

Read the package leaflet and pen user manual before use.

Subcutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
Discard pen 30 days after first use.
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Once in use: Store below 25 °C for 30 days.
Do not store with needle attached.
Recap pen to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/06/362/001
EU/1/06/362/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

byetta 5

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.
18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
### MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

#### PRE-FILLED PEN LABEL

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</strong></td>
<td></td>
</tr>
<tr>
<td>Byetta 5 mcg injection</td>
<td>exenatide</td>
</tr>
<tr>
<td></td>
<td>Subcutaneous use</td>
</tr>
<tr>
<td><strong>2. METHOD OF ADMINISTRATION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
<td></td>
</tr>
<tr>
<td>EXP</td>
<td></td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
<td></td>
</tr>
<tr>
<td>Lot</td>
<td></td>
</tr>
<tr>
<td><strong>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</strong></td>
<td></td>
</tr>
<tr>
<td>60 doses (1.2 mL)</td>
<td></td>
</tr>
<tr>
<td><strong>6. OTHER</strong></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca AB</td>
<td></td>
</tr>
<tr>
<td>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>CARTON</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Byetta 10 micrograms solution for injection in pre-filled pen exenatide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each dose contains 10 micrograms exenatide.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannitol, glacial acetic acid, sodium acetate trihydrate, water for injections. Also contains metacresol. See package leaflet for further information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solution for injection</td>
</tr>
<tr>
<td>1 pen (60 doses)</td>
</tr>
<tr>
<td>3 pens (3 x 60 doses)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twice daily</td>
</tr>
<tr>
<td>Read the package leaflet and pen user manual before use.</td>
</tr>
<tr>
<td>Subcutaneous use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
<tr>
<td>Discard pen 30 days after first use.</td>
</tr>
</tbody>
</table>
### 9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Once in use: Store below 25 ºC for 30 days. Do not store with needle attached.
Recap pen to protect from light.

### 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

### 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

### 12. MARKETING AUTHORISATION NUMBER(S)

EU/1/06/362/003
EU/1/06/362/004

### 13. BATCH NUMBER

Lot

### 14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

### 15. INSTRUCTIONS ON USE

### 16. INFORMATION IN BRAILLE

byetta 10

### 17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

### 18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRE-FILLED PEN LABEL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Byetta 10 mcg injection</td>
</tr>
<tr>
<td>exenatide</td>
</tr>
<tr>
<td>Subcutaneous use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. METHOD OF ADMINISTRATION</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 doses (2.4 mL)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca AB</td>
</tr>
</tbody>
</table>
B. PACKAGE LEAFLET
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or diabetes nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects talk to your doctor, pharmacist, or diabetes nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Byetta is and what it is used for
2. What you need to know before you use Byetta
3. How to use Byetta
4. Possible side effects
5. How to store Byetta
6. Contents of the pack and other information

1. What Byetta is and what it is used for

Byetta contains the active substance exenatide. It is an injectable medicine used to improve blood sugar control in adults with type 2 (non-insulin dependent) diabetes mellitus.

Byetta is used with other diabetic medicines called metformin, sulphonylureas, thiazolidinediones and basal or long acting insulins. Your doctor is now prescribing Byetta as an additional medicine to help control your blood sugar. Continue to follow your food and exercise plan.

You have diabetes because your body does not make enough insulin to control the level of sugar in your blood or if your body is not able to use the insulin properly. The medicine in Byetta helps your body to increase the production of insulin when your blood sugar is high.

2. What you need to know before you use Byetta

Do not use Byetta:

- If you are allergic to exenatide or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or diabetes nurse before using Byetta about the following:

- Using this medicine in combination with a sulphonylurea, as low blood sugar (hypoglycaemia) can occur. Ask your doctor, pharmacist, or diabetes nurse if you are not sure if any of your other medicines contain a sulphonylurea.
- If you have type 1 diabetes or diabetic ketoacidosis (a dangerous condition that can occur in diabetes), as you should not use this medicine.
- How to inject this medicine. It should be injected under the skin and not into a vein or into the muscle.
- If you have severe problems with slow stomach emptying or food digestion, as the use of this medicine is not recommended. The active substance in this medicine slows stomach emptying so food passes more slowly through your stomach.
- If you have ever had inflammation of the pancreas (pancreatitis) (see section 4).
- If you lose weight too quickly (more than 1.5 kg per week) talk to your doctor about it since this may cause problems such as gallstones.
- If you have severe kidney disease or you are on dialysis, as the use of this medicine is not recommended. There is little experience with this medicine in patients with kidney problems.

Byetta is not an insulin and should therefore not be used as a substitute for insulin.

Children and adolescents

Do not give this medicine to children and adolescents less than 18 years as there is no experience with this medicine in this age group.

Other medicines and Byetta

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, particularly:
- medicines that are used to treat type 2 diabetes that work like Byetta (e.g. liraglutide and prolonged-release exenatide), as taking these medicines with Byetta is not recommended.
- medicines used to thin the blood (anticoagulants), e.g. warfarin, as you will require additional monitoring of changes in INR (measurement of blood thinning) during initiation of therapy with this medicine.

Ask your doctor if the time at which you take any tablets should be changed because this medicine slows stomach emptying and can affect medicines that need to pass through the stomach quickly, e.g.
- Stomach resistant tablets or capsules (e.g. medicines that reduce stomach acid (proton pump inhibitors)) that should not stay too long in your stomach, may need to be taken an hour before, or four hours after this medicine.
- Some antibiotics may need to be taken an hour before your Byetta injection.
- For tablets that you need to take with food, it may be best if they are taken at a meal at a time when this medicine is not being administered.

Byetta with food

Use this medicine at any time within the 60 minutes (1 hour) before your meal. (See section 3 “How to use Byetta”). Do not use this medicine after your meal.

Pregnancy and breast-feeding

It is not known if this medicine may harm your unborn child. If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine, as it should not be used during pregnancy.

It is not known if exenatide passes into your milk. This medicine should not be used if breast-feeding.

Driving and using machines

If you use this medicine in combination with a sulphonylurea or insulin, low blood sugar (hypoglycaemia) can occur. Hypoglycaemia may reduce your ability to concentrate. Please keep this
possible problem in mind in all situations where you might put yourself and others at risk (e.g. driving a car or using machines).

**Byetta contains metacresol**
Metacresol may cause allergic reactions.

**Byetta contains sodium**
This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”.

### 3. How to use Byetta

Always use this medicine exactly as your doctor, pharmacist, or diabetes nurse has told you. Check with your doctor, pharmacist, or diabetes nurse if you are not sure.

Two strengths of Byetta are available: Byetta 5 micrograms and Byetta 10 micrograms. Your doctor may tell you to use Byetta 5 micrograms twice a day to start with. After using Byetta 5 micrograms twice a day for 30 days the doctor may increase your dose to Byetta 10 micrograms twice a day.

If you are over 70 years old or have problems with your kidneys it may take longer than 30 days to tolerate the Byetta 5 micrograms dose and so your doctor may not increase your dose.

One injection of your pre-filled pen will give you your dose. Do not change your dose unless your doctor has told you to.

You should inject this medicine at any time within the 60 minutes (1 hour) **before** your morning and evening meals, or before your two main meals of the day, which should be about 6 hours or more apart. **Do not** use this medicine **after** your meal.

You should inject this medicine under the skin (subcutaneous injection) of your upper leg (thigh), stomach area (abdomen), or upper arm. If you are using Byetta and an insulin you must make two separate injections.

You will **not** need to test your sugar levels on a day-by-day basis to set the dose of Byetta. However, if you are also using a sulphonylurea or an insulin your doctor may tell you to check your blood sugar levels to adjust the dose of sulphonylurea or insulin. If you are using insulin, your doctor will tell you how to reduce the dose of insulin and will recommend that you monitor your blood sugar more frequently, in order to avoid hyperglycaemia (high blood sugar) and diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to break down glucose because there is not enough insulin).

*See the accompanying Pen User Manual for instructions for using the Byetta Pen.*

Your doctor or nurse must teach you how to inject Byetta before you use it for the first time.

Becton, Dickinson and Company needles are suitable to use with the Byetta pen. Injection needles are not included.

Use a new injection needle for each injection and dispose of it after each use. This medicine is for you; never share a Byetta pen with others.

**If you use more Byetta than you should**

If you use more of this medicine than you should, talk to a doctor or go to a hospital right away. Using too much of this medicine can cause nausea, vomiting, dizziness, or symptoms of low blood sugar (see section 4).
If you forget to use Byetta

If you miss a dose of this medicine, skip that dose and use your next dose at the next prescribed time. **Do not** use an extra dose or increase the amount of your next dose to make up for the one you missed.

If you stop using Byetta

If you feel you should stop using this medicine, consult your doctor first. If you stop using this medicine this can affect your blood sugar levels.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or diabetes nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Severe allergic reactions** (anaphylaxis) have been reported rarely (may affect up to 1 in 1,000 people).

You should see your doctor immediately if you experience symptoms such as
- Swelling of the face, tongue or throat (angioedema)
- Rashes, itching and rapid swelling of the tissues of the neck, face, mouth or throat
- Difficulty to swallow
- Hives and difficulties to breathe

**Cases of inflammation of the pancreas** (pancreatitis) have been reported (frequency not known) in patients receiving this medicine. Pancreatitis can be a serious, potentially life-threatening medical condition.

- Tell your doctor if you have had pancreatitis, gallstones, alcoholism or very high triglycerides. These medical conditions can increase your chance of getting pancreatitis, or getting it again, whether or not you are taking this medicine.
- STOP taking this medicine and contact your doctor immediately if you experience **severe and persistent** stomach pain, with or without vomiting, because you could have an inflamed pancreas (pancreatitis).

**Very common** side effects (may affect more than 1 in 10 people):
- nausea, (nausea is most common when first starting this medicine, but decreases over time in most patients)
- vomiting
- diarrhoea
- hypoglycaemia

When this medicine is used with a medicine that contains a **sulphonylurea or an insulin**, episodes of low blood sugar (hypoglycaemia, generally mild to moderate) can occur very commonly. The dose of your sulphonylurea or insulin medicine may need to be reduced while you use this medicine. The signs and symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, and feeling jittery. Your doctor should tell you how to treat low blood sugar.

**Common** side effects (may affect up to 1 in 10 people):
- dizziness
- headache
- feeling jittery
• constipation
• pain in the stomach area
• bloating
• indigestion
• itching (with or without rash)
• flatulence (passing gas)
• increased sweating
• loss of energy and strength
• heartburn
• reduced appetite

This medicine may reduce your appetite, the amount of food you eat, and your weight.

If you lose weight too quickly (more than 1.5 kg per week) talk to your doctor about it since this may cause problems such as gallstones.

**Uncommon** side effects (may affect up to 1 in 100 people):
• decreased in kidney function
• dehydration, generally associated with nausea, vomiting and/or diarrhoea
• unusual taste in the mouth
• burping
• injection site reactions (redness)
• sleepiness
• hair loss
• weight decreased
• a delay in the emptying of the stomach
• inflamed gallbladder
• gallstones

**Rare** side effects (may affect up to 1 in 1,000 people):
• intestinal obstruction (blockage in intestine)

**Not known** (frequency cannot be estimated from the available data).

In addition some **other side effects** have been reported:
• bleeding or bruising more easily than normal due to low level of blood platelets.
• changes in INR (measurement of blood thinning) have been reported when used together with warfarin.

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or diabetes nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Byetta**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date, which is stated on the label and the carton after ‘EXP’. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Once in use, keep your pen below 25 °C for 30 days. Dispose of a used pen after 30 days, even if some medicine remains in the pen.

Replace the cap on the pen in order to protect from light. Do not freeze. Throw away any Byetta pen that has been frozen.
Do not use this medicine if you notice particles in the solution, or if it is cloudy or coloured.

Do not store the pen with the needle attached. If the needle is left on, medicine may leak from the pen or air bubbles may form in the cartridge.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Byetta contains

- The active substance is exenatide.
- Two pre-filled pens are available. One to deliver doses of 5 micrograms and one 10 micrograms.
- Each dose of Byetta 5 micrograms solution for injection (injection) contains 5 micrograms exenatide in 20 microlitre.
- Each dose of Byetta 10 micrograms solution for injection (injection) contains 10 micrograms exenatide in 40 microlitre.
- Each millilitre (mL) of the solution for injection contains 0.25 milligrams (mg) of exenatide.
- The other ingredients are metacresol, (44 micrograms/dose in Byetta 5 micrograms solution for injection and 88 micrograms/dose in Byetta 10 micrograms solution for injection), mannitol, glacial acetic acid, sodium acetate trihydrate and water for injections (see section 2).

What Byetta looks like and contents of the pack

Byetta is a clear and colourless liquid (solution for injection) filled in a glass cartridge within a pen. When the pen is empty, you cannot use it again. Each pen has 60 doses to provide 30 days of twice–a–day injections.

Byetta is available in pack sizes of 1 and 3 pre-filled pens. Not all pack sizes may be marketed.

Marketing Authorisation Holder
AstraZeneca AB
SE-151 85 Södertälje
Sweden

Manufacturer
AstraZeneca AB
Karlebyhusentrén Astraallén
SE-152 57 Södertälje
Sweden

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
AstraZeneca S.A./N.V.
Tel: +32 2 370 48 11

Lietuva
UBAstraZeneca Lietuva
Tel: +370 5 2660550

България
АстраЗенека България ЕООД
Тел.: +359 24455000

Luxembourg/Luxemburg
AstraZeneca S.A./N.V.
Tél/Tel: +32 2 370 48 11
<table>
<thead>
<tr>
<th>Country</th>
<th>Company Name</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Česká republika</td>
<td>AstraZeneca Czech Republic s.r.o.</td>
<td>+420 222 807 111</td>
</tr>
<tr>
<td>Danmark</td>
<td>AstraZeneca A/S</td>
<td>+45 43 66 64 62</td>
</tr>
<tr>
<td>Deutschland</td>
<td>AstraZeneca GmbH</td>
<td>+49 40 809034100</td>
</tr>
<tr>
<td>Eesti</td>
<td>AstraZeneca</td>
<td>+372 6549 600</td>
</tr>
<tr>
<td>Elláda</td>
<td>AstraZeneca A.E.</td>
<td>+30 210 6871500</td>
</tr>
<tr>
<td>España</td>
<td>AstraZeneca Farmacéutica Spain, S.A.</td>
<td>+34 91 301 91 00</td>
</tr>
<tr>
<td>France</td>
<td>AstraZeneca</td>
<td>+33 1 41 29 40 00</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>AstraZeneca d.o.o.</td>
<td>+385 1 4628 000</td>
</tr>
<tr>
<td>Ireland</td>
<td>AstraZeneca Pharmaceuticals (Ireland) Ltd</td>
<td>+353 1609 7100</td>
</tr>
<tr>
<td>Ísland</td>
<td>Vistor hf.</td>
<td>+354 535 7000</td>
</tr>
<tr>
<td>Italia</td>
<td>AstraZeneca S.p.A.</td>
<td>+39 02 00704500</td>
</tr>
<tr>
<td>Kıpros</td>
<td>Αλέξεωρ Φαρμακευτική Λτδ</td>
<td>+357 22490305</td>
</tr>
<tr>
<td>Latvija</td>
<td>SIA AstraZeneca Latvija</td>
<td>+371 67377100</td>
</tr>
<tr>
<td>Magyarország</td>
<td>AstraZeneca Kft.</td>
<td>+36 1 883 6500</td>
</tr>
<tr>
<td>Malta</td>
<td>Associated Drug Co. Ltd</td>
<td>+356 2277 8000</td>
</tr>
<tr>
<td>Nederland</td>
<td>AstraZeneca BV</td>
<td>+31 79 363 2222</td>
</tr>
<tr>
<td>Norge</td>
<td>AstraZeneca AS</td>
<td>+47 21 00 64 00</td>
</tr>
<tr>
<td>Österreich</td>
<td>AstraZeneca Österreich GmbH</td>
<td>+43 1 711 31 0</td>
</tr>
<tr>
<td>Polska</td>
<td>AstraZeneca Pharma Poland Sp. z o.o.</td>
<td>+48 22 245 73 00</td>
</tr>
<tr>
<td>Portugal</td>
<td>AstraZeneca Produtos Farmacéuticos, Lda.</td>
<td>+351 21 434 61 00</td>
</tr>
<tr>
<td>România</td>
<td>AstraZeneca Pharma SRL</td>
<td>+40 21 317 60 41</td>
</tr>
<tr>
<td>Slovenija</td>
<td>AstraZeneca UK Limited</td>
<td>+386 1 51 35 600</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>AstraZeneca AB, o.z.</td>
<td>+421 2 5737 7777</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>AstraZeneca Oy</td>
<td>+358 10 23 010</td>
</tr>
<tr>
<td>Sverige</td>
<td>AstraZeneca AB</td>
<td>+46 8 553 26 000</td>
</tr>
<tr>
<td>United Kingdom (Northern Ireland)</td>
<td>AstraZeneca UK Ltd</td>
<td>+44 1582 836 836</td>
</tr>
</tbody>
</table>

**This leaflet was last revised in**

Detailed information on this medicine is available on the European Medicines Agency web site: [http://www.ema.europa.eu](http://www.ema.europa.eu)
USER MANUAL CONTENTS

Section 1 – WHAT YOU NEED TO KNOW ABOUT YOUR BYETTA PEN
Section 2 – GETTING STARTED: FOR FIRST TIME USERS OR NEW PENS
Section 3 – ROUTINE USE: FOR PEOPLE WHO HAVE SET UP THEIR PEN
Section 4 – COMMONLY ASKED QUESTIONS: FOR QUESTIONS RELATED TO THE PEN

Section 1. WHAT YOU NEED TO KNOW ABOUT YOUR BYETTA PEN

Read this section completely before you begin. Then, move on to section 2 – getting started.

Read these instructions carefully BEFORE using your Byetta pen. Also, read the Byetta Package leaflet that comes with the Byetta pen carton.

You need to use the pen correctly in order to get the most benefit from Byetta. Failure to follow these instructions completely may result in a wrong dose, a broken pen or an infection.

These instructions do not take the place of talking with your healthcare professional about your medical condition or your treatment. If you are having problems using your Byetta pen, contact your healthcare professional.

IMPORTANT INFORMATION ABOUT YOUR BYETTA PEN

- Byetta is injected twice a day, the pen contains enough medicine for 30 days. You do not have to measure any doses, the pen measures each dose for you.
- DO NOT TRANSFER THE MEDICINE IN THE BYETTA PEN TO A SYRINGE.
- If any part of your pen appears broken or damaged, do not use the pen.
- Do not share your pen or needles as this may risk transmission of infectious agents.
- This pen is not recommended for use by people who are blind or who cannot see well enough. Help will be needed by a person trained to use the pen.
- Healthcare professionals or other caregivers should follow local or institutional policies regarding needle handling.
- Follow the instructions for hygienic injection technique recommended by your healthcare professional.
- Follow Section 2 only to set up a new pen before first use.
- Section 3 of this manual should be used for every injection.

ABOUT INJECTION NEEDLES

Your Byetta pen is suitable for use with Becton, Dickinson and Company pen injection needles.

Do I use a new needle for each injection?

- Yes. Do not reuse needles.
- Remove the needle immediately after each injection. This will help prevent leakage of Byetta, keep out air bubbles, reduce needle clogs, and decrease the risk of infection.
- Never push the injection button on the pen unless a needle is attached.
How do I throw away my needles?
- Throw away used needles in a puncture-resistant container or as recommended by your healthcare professional.
- Do not throw away the pen with a needle attached.

STORING YOUR BYETTA PEN

How do I store my Byetta pen?
- Store in a refrigerator (2 °C to 8 °C).
- Do not freeze. Throw away any Byetta pen that has been frozen.
- Once in use, your Byetta pen should be kept below 25 °C.
- Replace the cap on the pen in order to protect from light.
- Do not store the Byetta pen with the needle attached. If the needle is left on, medicine may leak from the Byetta pen or air bubbles may form in the cartridge.

Keep your pen and needles out of the sight and reach of children.

How long can I use a Byetta pen?
- Use a Byetta pen for only 30 days after setting up a new pen for first use.
  **Dispose of a used Byetta pen after 30 days, even if some medicine remains in the pen.**
- Mark the date when you first used your pen and the date 30 days later in the spaces below:

  **Date of first use**
  **Date to throw away pen**

  - Do not use Byetta after the expiry date, which is stated on the label and the carton after ‘EXP’. The expiry date refers to the last date of that month.

How do I clean my Byetta pen?
- If needed, wipe the outside of the pen with a clean, damp cloth.
- White particles may appear on the outside tip of the cartridge during normal use. You may remove them with an alcohol wipe or alcohol swab.

Please see the accompanying Byetta Package Leaflet. For additional information, contact your healthcare professional.

Section 2. GETTING STARTED

Read and follow the directions in this section only after you’ve read section 1-what you need to know about your Byetta pen.

Set up your new pen just before you use it for the first time. Follow the **New Pen Setup** only **once**. For routine use, **do not repeat** the New Pen Setup. If you do, you will run out of Byetta before 30 days of use.
BYETTA PEN PARTS

NEEDLE PARTS
(Needles Not Included)

DOSE WINDOW SYMBOLS

ready to pull dose knob out
ready to turn to dose position
ready to inject 5 micrograms (mcg)
dose knob pushed in and ready to reset

NEW PEN SETUP – DO THIS ONE TIME ONLY

STEP A Check the Pen

- Wash hands prior to use.
- Check pen label to make sure it is your 5 microgram pen.
- Pull off the blue pen cap.

Check Byetta in the cartridge. The liquid should be clear, colourless, and free of particles. If it is not, do not use.

Note: A small air bubble in the cartridge is normal

STEP B Attach the Needle

- Remove paper tab from outer needle shield.
- Push outer needle shield containing the needle straight onto the pen, then screw needle on until secure.
• Pull off outer needle shield. **Do not** throw away. The outer needle shield will be used when you are removing the needle from the pen after the injection.

• Pull off inner needle shield and throw away. A small drop of liquid may appear. This is normal.

**STEP C Dial the Dose**

• Check that the ⬆️ is in the dose window. If not, turn dose knob clockwise **until it stops** and the ⬅️ is in the dose window.

• **Pull dose knob out until it stops** and the ⬆️ is in the dose window.

• **Turn dose knob clockwise until it stops** at 5. Make sure that the 5 with the line under it is in the centre of the dose window.

**Note**: If you cannot turn the dose knob clockwise to the 5, see **Commonly Asked Questions**, number 9, in Section 4 of this user manual.
STEP D Prepare the Pen

- Point the needle of the pen up and away from you.

PUSH & HOLD

- **Use thumb to firmly push the injection button in until it stops**, then continue holding the injection button in while **slowly counting to 5.**
- **If you do not see a stream or several drops come from the needle tip, repeat Steps C & D.**

- Pen preparation is complete when the is in the centre of the dose window AND you have seen a stream or several drops come from the needle tip.

**Note:** If you do not see liquid after 4 times, see Commonly Asked Questions, number 3, in Section 4 of this user manual.

STEP E Complete New Pen Setup

- **Turn dose knob clockwise until it stops** and the is in the dose window.
- New Pen Setup is now done. Do not repeat Section 2 for routine use, if you do, you will run out of Byetta before 30 days of use.
- You are now ready for your first dose of Byetta.
- **Go to Section 3, Step 3, for instructions on how to inject your first routine dose.**

**Note:** If you cannot turn the dose knob, see Commonly Asked Questions, number 9, Section 4 of this user manual.

Section 3. ROUTINE USE

Now that you have done the New Pen Setup, follow Section 3 for all of your injections.
STEP 1 Check the Pen

- Wash hands prior to use.
- Check pen label to make sure it is your 5 microgram pen.
- Pull off the blue pen cap.

- Check Byetta in the cartridge.
  The liquid should be clear, colourless, and free of particles. If it is not, do not use.

**Note:** A small air bubble will not harm you or affect your dose.

STEP 2 Attach the Needle

- Remove paper tab from outer needle shield.
- **Push** outer needle shield containing the needle **straight** onto the pen, then **screw** needle on until secure.

- Pull off outer needle shield. **Do not** throw away. The outer needle shield will be used when you are removing the needle from the pen after the injection.

- Pull off inner needle shield and throw away. A small drop of liquid may appear. This is normal.

**Note:** If the needle is not secure, you may not get your full dose.
STEP 3 Dial the Dose

- Check that the 
  is in the dose window. If not, turn dose knob clockwise until it stops and the 
  is in the dose window.

- Pull dose knob out until it stops and the 
  is in the dose window.

- Turn dose knob clockwise until it stops at 
  . Make sure that the 5 with the line under it is in the centre of the dose window.

Note: If you cannot turn the dose knob clockwise to the 
, see Commonly Asked Questions, number 9, in Section 4 of this user manual.

STEP 4 Inject the Dose

- Grip pen firmly.
- Avoid tightly pinching the skin before injecting. Insert needle into skin using hygienic injection technique recommended by your healthcare professional.

PUSH & HOLD
- Use thumb to firmly push injection button in until it stops, then continue holding the injection button in while slowly counting to 5 in order to get a full dose.
• Keep the pressure on the injection button as you remove the needle from your skin, this keeps the medication in the cartridge clear. See Commonly Asked Question 4.

![Image](image1)

• Injection is complete when the ▲ is in the centre of the dose window.
• The pen is now ready to reset.

**Note:** If you see several drops of Byetta leaking from the needle after the injection, the injection button was not pushed in all the way. See Commonly Asked Questions, number 5, in Section 4 of this user manual.

**STEP 5 Reset the Pen**

![Image](image2)

• Turn dose knob clockwise until it stops and the ▲ is in the dose window.

**Note:** This needs to be done after each injection

**Note:** If you cannot turn the dose knob, or if your pen leaks, your full dose has not been delivered. See Commonly Asked Questions, numbers 5 and 9, in Section 4 of this user manual.

**STEP 6 Remove and Dispose of the Needle**

![Image](image3)

• Carefully put the outer needle shield back over the needle.
• **Remove the needle after each injection.** This prevents the liquid from leaking out.

![Image](image4)

• Unscrew the needle.
• Replace blue pen cap on pen before storage.
• Throw away needles in a puncture-resistant container or as recommended by your healthcare professional.

STEP 7 Store Pen for Next Dose

• Store your Byetta pen properly. (See Storing Your Byetta Pen in Section 1 of this user manual for more information.)
• When it is time for your next routine dose, go to Section 3, Step 1, and repeat Steps 1 - 7.

Section 4. COMMONLY ASKED QUESTIONS

1. Do I need to do the New Pen Setup before every dose?
• No. The New Pen Setup is done only once, just before each new pen is used for the first time.
• The purpose of the setup is to make sure that your Byetta pen is ready to use for the next 30 days.
• If you repeat the New Pen Setup before each routine dose, you will not have enough Byetta for 30 days. The small amount of Byetta used in the New Pen Setup will not affect the 30-day supply of Byetta.

2. Why are there air bubbles in the cartridge?
• A small air bubble is normal. It will not harm you or affect your dose.
• If the pen is stored with a needle attached, air bubbles may form in the cartridge. Do not store the pen with the needle attached.

3. What should I do if Byetta does not come out of the needle tip after four tries during New Pen Setup?
• Remove the needle by carefully putting the outer needle shield back over the needle. Unscrew and dispose of properly.
• Attach a new needle and repeat New Pen Setup, Steps B – E, in Section 2 of this user manual. Once you see several drops or a stream of liquid coming out of the tip of the needle, the setup is complete.

4. Why do I see particles in the cartridge after I finish my injection?
Particles or discoloration may appear in the cartridge after an injection. This may happen if the skin is pinched too tightly or if the pressure on the injection button is released before the needle is removed from the skin.

5. Why do I see Byetta leaking from my needle after I have finished my injection?
It is normal for a single drop to remain on the tip of your needle after your injection is complete. If you see more than one drop:
• You may not have received your full dose. Do not inject another dose. Consult with your healthcare professional about how to handle a partial dose.
• To prevent this, for your next dose, firmly push and hold the injection button in and slowly count to 5 (see Section 3, Step 4: Inject the Dose).

6. What do the arrows mean?
The arrows mean you are ready for the next step. These arrows show the direction to pull or turn the dose knob in the next step. This symbol means the dose knob is pushed in and the pen is ready to reset.

7. How can I tell when the injection is complete?
The injection is complete when:
• You have firmly pushed the injection button in all the way until it stops and
8. Where should I inject Byetta?
Byetta should be injected into your abdomen, thigh, or upper arm using the injection technique recommended by your healthcare professional.

9. What if I cannot pull, turn, or push the dose knob?
Check the symbol in the dose window. Follow the steps next to the matching symbol.

If 🔄 is in the dose window:
- Pull the dose knob out until 🔄 appears.

If 🔄 is in the dose window and the dose knob will not turn:
- The cartridge in your Byetta pen may not have enough liquid to deliver a full dose. A small amount of Byetta will always remain in the cartridge. If the cartridge contains a small amount or looks empty, obtain a new Byetta pen.

If 🔄 and part of the 5 are in the dose window and the dose knob cannot be pushed in:
- The dose knob was not turned all the way. Continue turning the dose knob clockwise until 5 is in the centre of the dose window.

If part of 5 and part of 🔄 are in the dose window and the dose knob cannot be pushed in:
- The needle may be clogged, bent, or incorrectly attached.
- Attach a new needle. Make sure needle is on straight and screwed on all the way.
- Firmly push the injection button in all the way. Byetta should come from needle tip.

If 🔄 is in the dose window and the dose knob will not turn:
- The injection button was not pushed in all the way and a complete dose was not delivered. Consult with your healthcare professional about how to handle a partial dose.
  - Follow these steps to reset your pen for your next injection:
    - Firmly push the injection button in all the way until it stops. Keep holding the injection button in and slowly count to 5. Then turn the dose knob clockwise until 🔄 appears in the dose window.
    - If you cannot turn the dose knob, the needle may be clogged. Replace the needle and repeat the step above.
  - For your next dose, be sure to firmly push and hold the injection button in and slowly count to 5 before removing needle from skin.
Please see the accompanying Package Leaflet. For additional information contact your healthcare professional.
User Manual

Section 1 – WHAT YOU NEED TO KNOW ABOUT YOUR BYETTA PEN
Read this section completely before you begin. Then, move on to section 2 – getting started.

Read these instructions carefully BEFORE using your Byetta pen. Also read the Byetta Package leaflet that comes with the Byetta pen carton.

You need to use the pen correctly in order to get the most benefit from Byetta. Failure to follow these instructions completely may result in a wrong dose, a broken pen or an infection.

These instructions do not take the place of talking with your healthcare professional about your medical condition or your treatment. If you are having problems using your Byetta pen, contact your healthcare professional.

IMPORTANT INFORMATION ABOUT YOUR BYETTA PEN

- Byetta is injected twice a day, the pen contains enough medicine for 30 days. You do not have to measure any doses, the pen measures each dose for you.
- **DO NOT TRANSFER THE MEDICINE IN THE BYETTA PEN TO A SYRINGE.**
- If any part of your pen appears broken or damaged, do not use the pen.
- **Do not share your pen or needles as this may risk transmission of infectious agents.**
- This pen is not recommended for use by people who are blind or who cannot see well enough. Help will be needed by a person trained to use the pen.
- Healthcare professionals or other caregivers should follow local or institutional policies regarding needle handling.
- **Follow the instructions for hygienic injection technique recommended by your healthcare professional.**
- Follow Section 2 only to set up a new pen before first use.
- Section 3 of this manual should be used for every injection.

ABOUT INJECTION NEEDLES

Your Byetta pen is suitable for use with Becton, Dickinson and Company pen injection needles.

**Do I use a new needle for each injection?**

- Yes. Do not reuse needles.
- Remove the needle immediately after each injection. This will help prevent leakage of Byetta, keep out air bubbles, reduce needle clogs, and decrease the risk of infection.
- Never push the injection button on the pen unless a needle is attached.
How do I throw away my needles?
• Throw away used needles in a puncture-resistant container or as recommended by your healthcare professional.
• Do not throw away the pen with a needle attached.

STORING YOUR BYETTA PEN

How do I store my Byetta pen?
• Store in a refrigerator (2 ºC to 8 ºC).
• Do not freeze. Throw away any Byetta pen that has been frozen.
• Once in use, your Byetta pen should be kept below 25 ºC.
• Replace the cap on the pen in order to protect from light.
• Do not store the Byetta pen with the needle attached. If the needle is left on, medicine may leak from the Byetta pen or air bubbles may form in the cartridge.

Keep your pen and needles out of the sight and reach of children.

How long can I use a Byetta pen?
• Use a Byetta pen for only 30 days after setting up a new pen for first use.
  
  Dispose of a used Byetta pen after 30 days, even if some medicine remains in the pen
  
  Mark the date when you first used your pen and the date 30 days later in the spaces below:

  Date of first use
  Date to throw away pen

• Do not use Byetta after the expiry date, which is stated on the label and the carton after ‘EXP’. The expiry date refers to the last date of that month.

How do I clean my Byetta pen?
• If needed, wipe the outside of the pen with a clean, damp cloth.
• White particles may appear on the outside tip of the cartridge during normal use. You may remove them with an alcohol wipe or alcohol swab.

Please see the accompanying Byetta Package Leaflet. For additional information, contact your healthcare professional.

Section 2. GETTING STARTED

Read and follow the directions in this section only after you’ve read section 1-what you need to know about your Byetta pen.

Set up your new pen just before you use it for the first time. Follow the New Pen Setup only once. For routine use, do not repeat the New Pen Setup. If you do, you will run out of Byetta before 30 days of use.
BYETTA PEN PARTS
Blue Pen Cap  Cartridge  Byetta Liquid  Label  Dose Window  Dose Knob  Injection Button

NEEDLE PARTS
(Needles Not Included)

DOSE WINDOW SYMBOLS

Outer Needle Shield  Inner Needle Shield  Needle Paper Tab

ready to pull dose knob out
ready to turn to dose position
ready to inject 10 micrograms (mcg)
dose knob pushed in and ready to reset

NEW PEN SETUP – DO THIS ONE TIME ONLY

STEP A Check the Pen

- Wash hands prior to use.
- Check pen label to make sure it is your 10 microgram pen.
- Pull off the blue pen cap.

Check Byetta in the cartridge. The liquid should be clear, colourless, and free of particles. If it is not, do not use.

Note: A small air bubble in the cartridge is normal

STEP B Attach the Needle

- Remove paper tab from outer needle shield.
- Push outer needle shield containing the needle straight onto the pen, then screw needle on until secure.
• Pull off outer needle shield. Do not throw away. The outer needle shield will be used when you are removing the needle from the pen after the injection.

• Pull off inner needle shield and throw away. A small drop of liquid may appear. This is normal.

**STEP C Dial the Dose**

• Check that the is in the dose window. If not, turn dose knob clockwise until it stops and the is in the dose window.

• Pull dose knob out until it stops and the is in the dose window.

• Turn dose knob clockwise until it stops at . Make sure that the 10 with the line under it is in the centre of the dose window.

*Note:* If you cannot turn the dose knob clockwise to the , see *Commonly Asked Questions*, number 9, in Section 4 of this user manual.
STEP D Prepare the Pen

- Point the needle of the pen up and away from you.

PUSH & HOLD
- Use thumb to firmly push the injection button in until it stops, then continue holding the injection button in while slowly counting to 5.
- If you do not see a stream or several drops come from the needle tip, repeat Steps C & D.

- Pen preparation is complete when the is in the centre of the dose window AND you have seen a stream or several drops come from the needle tip.

Note: If you do not see liquid after 4 times, see Commonly Asked Questions, number 3, in Section 4 of this user manual.

STEP E Complete New Pen Setup

- Turn dose knob clockwise until it stops and the is in the dose window.
- New Pen Setup is now done. Do not repeat Section 2 for routine use, if you do, you will run out of Byetta before 30 days of use.
- You are now ready for your first dose of Byetta.
- Go to Section 3, Step 3, for instructions on how to inject your first routine dose.

Note: If you cannot turn the dose knob, see Commonly Asked Questions, number 9, Section 4 of this user manual.

Section 3. ROUTINE USE

Now that you have done the New Pen Setup, follow Section 3 for all of your injections.
STEP 1 Check the Pen

- Wash hands prior to use.
- Check pen label to make sure it is your 10 microgram pen.
- Pull off the blue pen cap.
- Check Byetta in the cartridge.
- The liquid should be clear, colourless, and free of particles. If it is not, do not use.

**Note:** A small air bubble will not harm you or affect your dose.

STEP 2 Attach the Needle

- Remove paper tab from outer needle shield.
- **Push** outer needle shield containing the needle **straight** onto the pen, then **screw** needle on until secure.
- Pull off outer needle shield. **Do not** throw away. The outer needle shield will be used when you are removing the needle from the pen after the injection.
- Pull off inner needle shield and throw away. A small drop of liquid may appear. This is normal.

**Note:** If the needle is not secure, you may not get your full dose.
STEP 3 Dial the Dose

- Check that the 10 is in the dose window. If not, turn dose knob clockwise until it stops and the 10 is in the dose window.

- Pull dose knob out until it stops and the 10 is in the dose window.

- Turn dose knob clockwise until it stops at 10. Make sure that the 10 with the line under it is in the centre of the dose window.

Note: If you cannot turn the dose knob clockwise to the 10, see Commonly Asked Questions, number 9, in Section 4 of this user manual.

STEP 4 Inject the Dose

- Grip pen firmly.
- Avoid tightly pinching the skin before injecting. Insert needle into skin using hygienic injection technique recommended by your healthcare professional.

PUSH & HOLD
- Use thumb to firmly push injection button in until it stops, then continue holding the injection button in while slowly counting to 5 in order to get a full dose.
• Keep the pressure on the injection button as you remove the needle from your skin, this keeps the medication in the cartridge clear. See Commonly Asked Question 4.

• Injection is complete when the ▲ is in the centre of the dose window.
• The pen is now ready to reset.

Note: If you see several drops of Byetta leaking from the needle after the injection, the injection button was not pushed in all the way. See Commonly Asked Questions, number 5, in Section 4 of this user manual.

STEP 5 Reset the Pen

• Turn dose knob clockwise until it stops and the ▲ is in the dose window.

Note: This needs to be done after each injection

Note: If you cannot turn the dose knob, or if your pen leaks, your full dose has not been delivered. See Commonly Asked Questions, numbers 5 and 9, in Section 4 of this user manual.

STEP 6 Remove and Dispose of the Needle

• Carefully put the outer needle shield back over the needle.
• Remove the needle after each injection. This prevents the liquid from leaking out.

• Unscrew the needle.
• Replace blue pen cap on pen before storage.
• Throw away needles in a puncture-resistant container or as recommended by your healthcare professional.

STEP 7 Store Pen for Next Dose

• Store your Byetta pen properly. (See Storing Your Byetta Pen in Section 1 of this user manual for more information.)
• When it is time for your next routine dose, go to Section 3, Step 1, and repeat Steps 1 - 7.

Section 4. COMMONLY ASKED QUESTIONS

1. Do I need to do the New Pen Setup before every dose?
• No. The New Pen Setup is done only once, just before each new pen is used for the first time.
• The purpose of the setup is to make sure that your Byetta pen is ready to use for the next 30 days.
• If you repeat the New Pen Setup before each routine dose, you will not have enough Byetta for 30 days. The small amount of Byetta used in the New Pen Setup will not affect the 30-day supply of Byetta.

2. Why are there air bubbles in the cartridge?
• A small air bubble is normal. It will not harm you or affect your dose.
• If the pen is stored with a needle attached, air bubbles may form in the cartridge. Do not store the pen with the needle attached.

3. What should I do if Byetta does not come out of the needle tip after four tries during New Pen Setup?
• Remove the needle by carefully putting the outer needle shield back over the needle. Unscrew and dispose of properly.
• Attach a new needle and repeat New Pen Setup, Steps B – E, in Section 2 of this user manual. Once you see several drops or a stream of liquid coming out of the tip of the needle, the setup is complete.

4. Why do I see particles in the cartridge after I finish my injection?
Particles or discolouration may appear in the cartridge after an injection. This may happen if the skin is pinched too tightly or if the pressure on the injection button is released before the needle is removed from the skin.

5. Why do I see Byetta leaking from my needle after I have finished my injection?
It is normal for a single drop to remain on the tip of your needle after your injection is complete. If you see more than one drop:
• You may not have received your full dose. Do not inject another dose. Consult with your healthcare professional about how to handle a partial dose.
• To prevent this, for your next dose, firmly push and hold the injection button in and slowly count to 5 (see Section 3, Step 4: Inject the Dose).

6. What do the arrows mean?
The arrows mean you are ready for the next step. These arrows show the direction to pull or turn the dose knob in the next step. This symbol means the dose knob is pushed in and the pen is ready to reset.

7. How can I tell when the injection is complete?
The injection is complete when:
• You have firmly pushed the injection button in all the way until it stops and
8. Where should I inject Byetta?
Byetta should be injected into your abdomen, thigh, or upper arm using the injection technique recommended by your healthcare professional.

9. What if I cannot pull, turn, or push the dose knob?
Check the symbol in the dose window. Follow the steps next to the matching symbol.

If ▲ is in the dose window:
- Pull the dose knob out until ▲ appears.

If ▲ is in the dose window and the dose knob will not turn:
- The cartridge in your Byetta pen may not have enough liquid to deliver a full dose. A small amount of Byetta will always remain in the cartridge. If the cartridge contains a small amount or looks empty, obtain a new Byetta pen.

If ▲ and part of ● are in the dose window and the dose knob cannot be pushed in:
- The dose knob was not turned all the way. Continue turning the dose knob clockwise until ● is in the centre of the dose window.

If part of ● and part of ▲ are in the dose window and the dose knob cannot be pushed in:
- The needle may be clogged, bent, or incorrectly attached.
- Attach a new needle. Make sure needle is on straight and screwed on all the way.
- Firmly push the injection button in all the way. Byetta should come from needle tip.

If ▲ is in the dose window and the dose knob will not turn:
- The injection button was not pushed in all the way and a complete dose was not delivered. Consult with your healthcare professional about how to handle a partial dose.
- Follow these steps to reset your pen for your next injection:
  - Firmly push the injection button in all the way until it stops. Keep holding the injection button in and slowly count to 5. Then turn the dose knob clockwise until ▲ appears in the dose window.
  - If you cannot turn the dose knob, the needle may be clogged. Replace the needle and repeat the step above.
- For your next dose, be sure to firmly push and hold the injection button in and slowly count to 5 before removing needle from skin.
Please see the accompanying Package Leaflet. For additional information contact your healthcare professional.